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kDBACKGROUND Several studies have demonstrated the tremendous potential of using coronary artery calcium (CAC) in
addition to traditional risk factors for coronary heart disease (CHD) risk prediction. However, to date, no risk score
incorporating CAC has been developed.
OBJECTIVES The goal of this study was to derive and validate a novel risk score to estimate 10-year CHD risk using CAC
and traditional risk factors.
METHODS Algorithm development was conducted in the MESA (Multi-Ethnic Study of Atherosclerosis), a prospective
community-based cohort study of 6,814 participants age 45 to 84 years, who were free of clinical heart disease at
baseline and followed for 10 years. MESA is sex balanced and included 39% non-Hispanic whites, 12% Chinese Ameri-
cans, 28% African Americans, and 22% Hispanic Americans. External validation was conducted in the HNR (Heinz Nixdorf
Recall Study) and the DHS (Dallas Heart Study).
RESULTS InclusionofCAC in theMESA risk scoreofferedsigniﬁcant improvements in riskprediction (C-statistic0.80vs.0.75;
p < 0.0001). External validation in both the HNR and DHS studies provided evidence of very good discrimination and cali-
bration. Harrell’s C-statistic was0.779 inHNR and0.816 in DHS. Additionally, the difference in estimated 10-year risk between
eventsandnoneventswasapproximately8%to9%, indicatingexcellentdiscrimination.Meancalibration,orcalibration-in-the-
large,wasexcellent forbothstudies,withaveragepredicted 10-year riskwithinone-half ofapercentof theobservedevent rate.
CONCLUSIONS An accurate estimate of 10-year CHD risk can be obtained using traditional risk factors and CAC.
The MESA risk score, which is available online on the MESA web site for easy use, can be used to aid clinicians when
communicating risk to patients and when determining risk-based treatment strategies. (J Am Coll Cardiol 2015;66:1643–53)
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1644C oronary artery calcium (CAC) scoresderived from routine cardiac-gatednoncontrast computed tomography
scans are a commonly used method for
enhancing clinical cardiovascular risk predic-
tion. Importantly, CAC scores are incremental
but not redundant with traditional risk fac-tors, and therefore, integration of both sets of informa-
tion can enhance risk assessment. Indeed, the added
value of CAC over and above traditional risk factors
for prediction of cardiovascular events has been
demonstrated in several studies (1–11). However,
to date, no published risk scores are available to clini-
cians to incorporate CAC into routine 10-year risk
prediction.SEE PAGES 1654 AND 1669The MESA (Multi-Ethnic Study of Atherosclerosis),
due to its population-based, multiethnic composition
and availability of 10 years of follow-up for incident
CHD events, provides a unique opportunity to des-
cribe how CAC might be optimally combined with
traditional risk factors in risk prediction. In this
paper, we describe a novel MESA risk score that can
be used to estimate 10-year CHD risk in patients with
a CAC measurement. We also provide a score without
inclusion of CAC for evaluation of the effect of
including CAC in the novel risk score. We believe that
the MESA risk score could be immediately used for
communication of risk with patients after CAC
scoring, to guide risk-based treatment decisions in
clinical practice, as well as in designing future
research studies that might use CAC to target high-
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STUDY PARTICIPANTS. MESA was designed to study
the prevalence, risk factors, and progression of sub-
clinical cardiovascular disease (CVD) in a multiethnic
cohort. A detailed description of the study design and
methods has been published previously (12). Brieﬂy,
6,814 participants age 45 to 84 years who identiﬁed
themselves as white, African-American, Hispanic, or
Chinese were recruited from 6 U.S. communities
from 2000 to 2002. All participants were free of
clinically apparent CVD. The research was approved
by the institutional review boards at all partici-
pating institutions, and all participants gave in-
formed consent.
MEASUREMENT OF CAC. CAC was measured using
electrocardiogram (ECG)-gated electron-beam com-
puted tomography at 3 ﬁeld centers and multi-
detector computed tomography at the other 3 ﬁeld
centers (12,13). Images were analyzed independently
at a central reading center, and the amount of CAC
was quantiﬁed using the Agatston scoring method
(14). Rescan agreement was high using both electron-
beam and multidetector computed tomography
scanners (15). Interobserver and intraobserver agree-
ment were also very high (Kappa ¼ 0.93 and 0.90,
respectively).
CORONARY HEART DISEASE ASCERTAINMENT. At
intervals of 9 to 12 months, a telephone interviewer
contacted each participant to inquire about interim
hospitalizations, cardiovascular outpatient diagnoses
and procedures, and deaths. Trained personnel ab-
stracted medical records, and 2 physicians inde-
pendently classiﬁed the events using pre-deﬁnediology, UCLA School of Medicine, Los Angeles, Cal-
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1645criteria. Hospital records were obtained for an esti-
mated 98% of hospitalized cardiovascular events
and some medical record-based information was
available for 95% of outpatient encounters. All events
through December 31, 2011, are included in this
report.
Our endpoint consisted of incident hard CHD
events: myocardial infarction (MI), resuscitated car-
diac arrest, fatal CHD, and revascularization only if
the participant also had prior or concurrent adjudi-
cated angina. An MI required either abnormal car-
diac biomarkers (2 times upper limits of normal)
regardless of pain or ECG ﬁndings; evolving Q waves
regardless of pain or biomarker ﬁndings; or a com-
bination of chest pain, ST-T evolution or new left
bundle branch block, and biomarker levels 1 to 2 times
upper limits of normal. For suspected cardiovascular
deaths based on International Classiﬁcation of
Diseases-10 underlying cause of death codes, a com-
mittee of MESA physicians classiﬁed CHD deaths
using the death certiﬁcate, available medical records,
and for out of hospital deaths, any next of kin in-
terviews or physician questionnaires that could be
obtained. A CHD death required a documented MI
within the previous 28 days, chest pain within 72 h, or
a history of CHD, and required the absence of a
known noncardiac cause of death.
MEASUREMENT OF OTHER COVARIATES. Positive
family history referred to a heart attack at any age in a
parent, sibling, or child. The age at which the relative
experienced the heart attack was not collected at
baseline in MESA, precluding consideration of pre-
mature family history. Current smoking was deﬁned
as answering yes to the question “Have you smoked
cigarettes during the last 30 days?” Resting blood
pressure was measured 3 times in the seated position,
and the average of the last 2 measurements was used
in analysis. Medication use was determined by
questionnaire. Additionally, participants were asked
to bring containers for all medications used during
the 2 weeks before the visit to the clinic.
STATISTICAL METHODS. Model development . Our
list of candidate covariates included the traditional
Framingham risk factors: age, sex, high-density lipo-
protein cholesterol, total cholesterol, systolic blood
pressure, antihypertensive medication use, current
smoking, diabetes, and CAC. Additionally we consid-
ered family history of heart attack, lipid-lowering
medication use, body mass index, and race/ethnicity.
Interactions considered included: age, sex, race/
ethnicity, and CAC with all other predictors; antihy-
pertensive medications by systolic blood pressure;
and lipid-lowering medications by total cholesterol.For continuous covariates, we explored nonlinearity
by ﬁtting generalized additive models with 4 degrees
of freedom and adjusted for age, sex, and race/
ethnicity (16). These models were ﬁt using the “gam”
package in Stata (17). There was evidence of
potential nonlinearity for age and systolic blood
pressure; hence, polynomial terms were considered.
Although substantial nonlinearity was exhibited for
untransformed CAC, the log(CAC þ 1) transformation,
which has been used previously (1), demonstrated no
departures from linearity. It is critical to use CAC
continuously to preserve all available information in
the CAC variable, as has been preferred in prior CAC
published data. The identical modeling strategy was
used to develop the model that did not include CAC.
Shrinkage/penalization methods were used to
avoid overﬁtting (18). We primarily used the method
called Lasso (“least absolute shrinkage and selection
operator”), which penalizes the sum of the absolute
values of the regression coefﬁcients (19,20). This
leads to some coefﬁcients shrinking all the way to 0,
and hence, simultaneously performs variable selec-
tion. A penalized Cox proportional hazards model was
used, and this was ﬁt using the “penalized” package
in R, version 3.1.1 (R Foundation for Statistical
Computing, Vienna, Austria) (21). Shrinkage was done
in 2 stages to allow inclusion of interaction terms only
when the corresponding main effects were in the
model. The ﬁrst stage forced in the main effects of
interest (unpenalized) and selected (via the Lasso)
among the interaction and polynomial terms. The
second stage started from the main effects plus
selected interaction terms (if any) and then applied a
ridge regression penalty. This penalty provides some
shrinkage of the coefﬁcients, but does not shrink any
of the coefﬁcients to 0. Selection of the tuning pa-
rameters at each stage was done via 10-fold cross-
validated likelihood.
Proportional hazards for each variable were tested
using Schoenfeld residuals in a standard Cox model
that forced in all of the candidate main effects (22).
There were no signiﬁcant proportional hazards vio-
lations for any of the candidate main effects, and the
global test was nonsigniﬁcant (p ¼ 0.33).
Externa l va l idat ion . The risk scores were validated
in 2 independent longitudinal cohort studies, HNR
and DHS. The risk score formula was sent to the
coordinating centers of these studies, where the
validation calculations were performed.
HNR is a single-center study that recruited a total of
4,814 Caucasians between 45 and 75 years of age from 3
neighboring cities in Germany between 2000 and 2003.
Participants were a random sample derived from
mandatory citizen registries. For this comparison of
TABLE 1
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1646the 2 study cohorts, we included 3,692 members of
HNR who were free of clinical CVD at baseline and for
whom complete covariate and follow-up data was
available. Details about the design and recruitment
strategy of the HNR have been previously published
(23,24). Additionally, prior publications have des-
cribed the comparability of the HNR andMESA cohorts
with respect to CAC measurement, risk factors, and
endpoints (25,26). Participants were followed for a
median of 10.4 years (IQR: 9.2 to 11.3 years). For all
primary study endpoints, hospital and nursing home
records, including electrocardiograms, laboratory
values, and pathology reports, were collected. For
deceased subjects, death certiﬁcates were collected
and interviews with general practitioners, relatives,
and eyewitnesseswere undertaken if possible.Medical
records were obtained in 100% of all reported end-
points. An external endpoint committee blinded for
risk factor status and CAC scores reviewed all docu-
ments and classiﬁed the endpoints.
The DHS is a multiethnic, population-based prob-
ability sample of Dallas County, Texas. The initialParticipant Characteristics—the MESA, HNR, and DHS Studies
MESA
(N ¼ 6,726)
HNR
(N ¼ 3,692)
DHS
(N ¼ 1,080)
62.1  10.2 59.8  7.7 52.7  5.5
3,176 (47.2) 1,714 (46.4) 466 (43.2)
icity
n 2,622 (38.5) 3,692 (100) 409 (37.9)
American 803 (11.8) — —
American 1,893 (27.8) — 530 (49.1)
American 1,496 (22.0) — 122 (11.3)
— — 19 (1.8)
859 (12.7) 470 (12.7) 148 (13.7)
oker 887 (13.0) 831 (22.5) 272 (25.2)
esterol, mg/dl 194.2  35.7 231.0  38.9 189.3  41.5
lesterol, mg/dl 51.0  14.8 58.8  17.0 51.4  14.9
wering medications 1,100 (16.2) 368 (10.0) 104 (9.6)
lood pressure, mm Hg 126.6  21.5 132.9  20.6 128.5  19.5
ertensive medications 2,536 (37.2) 1,241 (33.6) 330 (30.6)
tory of heart attack
3,611 (53.7) 2,671 (72.3) 436 (40.4)
2,699 (40.1) 1,021 (27.7) 501 (46.4)
n 416 (6.2) — 143 (13.2)
artery calcium (Agatston)
3,416 (50.1) 1,138 (30.8) 361 (33.4)
1,794 (26.3) 1,512 (40.9) 565 (52.3)
9 927 (13.6) 659 (17.9) 113 (10.5)
677 (9.9) 383 (10.4) 41 (3.8)
lan-Meier) CHD rate 6.5% 7.5% 5.5%
ean  SD or n (%). For DHS, the “Other” race/ethnic category includes the following:
dian/Paciﬁc Islander/Alaskan Native/Asian/East Indian.
oronary heart disease; DHS ¼ Dallas Heart Study; HDL ¼ high-density lipoprotein;
z Nixdorf Recall Study; MESA ¼ Multi-Ethnic Study of Atherosclerosis.data collection was performed in 2000 to 2002 and
included the collection of detailed socioeconomic,
biomarker, and imaging data from each participant.
Participants in DHS were age 30 to 65 years; however
only 1,080 subjects age 45 to 65 years were included
in this validation study. Details about the design of
the DHS have been previously published (27). The
DHS includes Caucasians, African Americans, and
Hispanics. Participants were followed for a median
of 9.3 years (IQR: 8.9 to 9.8 years). The DHS used
a redundant strategy to ascertain clinical events.
Death events were acquired for all DHS participants
through the National Death Index, which was
completed on December 31, 2010. Nonfatal events
were captured through an annual detailed health
survey administered by phone and by a unique data
source, the Dallas-Fort Worth Hospital Council Data
Initiative database, which captures hospital claims
data for 77 hospitals in the metroplex area and rep-
resents >90% of the health care market volume in
this region. More than 90% of participants from the
CAC cohort were tracked using 1 or both of these
mechanisms.
Performance metr i cs . We assessed 2 aspects of
model performance: discrimination and calibration.
Discrimination was assessed using Harrell’s C-
statistic, the discrimination slope (the absolute
difference between the average predicted 10-year
probability of an event for those who experienced an
event minus the average for those who did not), and
the area under the survival receiver-operator char-
acteristic (ROC) curve (18,28,29). Calibration was
assessed via the calibration slope (calculated as the
slope of the linear regression of the event indicator on
the predicted probability) and calibration-in-the-large
(the difference between the observed event rate and
the average predicted 10-year event rate) (18).
Presentat ion . A computerized version of the risk
score will be posted on the MESA Website for ease of
use by clinicians, patients, and researchers. This
MESA risk score application requires only the input of
the traditional risk factors and the CAC score and is
the preferred way for interested parties to use the risk
score.
RESULTS
Participants in MESA were followed for a median of
10.2 years (IQR: 9.7 to 10.7 years), and 422 CHD
events were observed, with ﬁrst events including
68 CHD deaths, 190 nonfatal MIs, 149 angina-driven
revascularizations, and 15 resuscitated cardiac ar-
rests. A total of 88 participants were excluded
from this study, (5 participants were found to have a
TABLE 2 MESA 10-Year CHD Risk Prediction Models
Risk Factors Only Risk Factors and CAC
Hazards Ratio Beta Coefﬁcient p Value Hazards Ratio Beta Coefﬁcient p Value
Age, yrs 1.05 0.0455 <0.0001 1.02 0.0172 .007
Male 2.12 0.7496 <0.0001 1.50 0.4079 <0.001
Race/ethnicity
Non-Hispanic white Ref 0 — Ref 0 —
Chinese American 0.60 0.5055 <0.01 0.71 0.3475 0.07
African American 0.81 0.2111 0.066 1.04 0.0353 0.70
Hispanic 0.83 0.1900 0.11 0.98 0.0222 0.88
Diabetes 1.68 0.5168 <0.0001 1.48 0.3892 0.002
Current smoker 1.61 0.4732 <0.001 1.45 0.3717 0.005
Total cholesterol, mg/dl 1.01 0.0053 <0.0001 1.00 0.0043 <0.001
HDL cholesterol, mg/dl 0.99 0.0140 <0.001 0.99 0.0114 0.003
Lipid-lowering meds 1.28 0.2473 0.003 1.13 0.1206 0.32
Systolic blood pressure, mm Hg 1.01 0.0085 0.0002 1.01 0.0066 0.004
Antihypertensive meds 1.40 0.3381 0.0013 1.26 0.2278 0.033
Family history of heart attack 1.57 0.4522 <0.0001 1.38 0.3239 <0.001
ln (CAC þ 1) NA NA NA 1.32 0.2743 <0.0001
Baseline survival at 10 yrs, S(10) 0.99963 0.99833
The p values are based on a standard Cox proportional hazards model. To estimate the 10-year risk of a CHD event for a particular person, multiply the values of the risk factors
by the corresponding beta coefﬁcient and sum these quantities up to yield a value (call it A following the notation in Wilson et al. [38]). Then calculate: B ¼ exp(A). Finally, the
10-year risk is given by 1  S(10)B. Alternatively, see the online calculator on the MESA Website.
CAC ¼ coronary artery calcium; other abbreviations as in Table 1.
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1647pre-baseline event, 28 were without follow-up, and 55
were missing covariate data). The remaining sample
size was 6,726.
Table 1 provides the baseline characteristics of the
MESA cohort and the 2 validation cohorts. All 3 co-
horts are sex balanced. DHS participants are 10 years
younger on average than participants in MESA and
HNR. HNR is exclusively Caucasian, whereas DHS
includes African Americans and Hispanic Americans,
similar to MESA. Rates of diabetes are similar across
cohorts. MESA includes fewer current smokers than
either HNR or DHS. MESA and DHS are similar in
terms of lipid levels, blood pressure, and family his-
tory of heart attack. HNR participants have worse
lipid proﬁles and blood pressure levels, but less pos-
itive family history of heart attack. Kaplan-Meier
10-year rates of CHD were highest for HNR (7.5%),
followed by MESA (6.5%), and ﬁnally DHS (5.5%).
Table 2 provides the estimated hazards ratios, co-
efﬁcients, and baseline hazards for a 10-year CHD risk
prediction model with and without CAC. The table
provides the baseline survival function and risk factor
coefﬁcients that have been incorporated into the on-
line MESA risk score application. No interaction or
polynomial terms were retained in the model, nor
were body mass index or diastolic blood pressure
included.
Figure 1 illustrates the internal discrimination
properties of our 2 models. The area under thesurvival ROC curve within MESA was 0.81 for the
model with CAC, indicating excellent discrimination
between events and nonevents. Comparison with our
internally developed risk score without CAC, which
has an area under the survival ROC of 0.76, provides
evidence of the signiﬁcant improvement due to in-
clusion of CAC (p < 0.0001). The boxplot in the sec-
ond panel of Figure 1 shows separation in predicted
10-year risk between events and nonevents, and this
is also improved by the addition of CAC. The differ-
ence between events and nonevents was signiﬁcant
for each version of the score (p < 0.001 for both).
The discrimination slope was 0.086 for the score with
CAC. That is, those who experienced events had an
average predicted 10-year risk that was 8.6% higher
than those who did not. In contrast, the discrimina-
tion slope was 0.052 for the score without CAC, or an
average separation of 5.2% higher predicted risk for
those with events.
We also evaluated our internal discrimination
performance in various subsets of the MESA cohort.
The area under the survival ROC was better for non-
Caucasians relative to Caucasians (Chinese: 0.85,
Black: 0.80, Hispanic: 0.86, Caucasian: 0.79), better
for young (under 65 years: 0.82) than old ($65 years:
0.76), and women (0.81) compared with men (0.79).
External validation in both the HNR and
DHS studies is shown in Table 3 and the Central
Illustration, and provides evidence for very good to
FIGURE 1 Discrimination of the MESA CHD Risk Score Within the Development Cohort
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(Left) Receiver-operator characteristic (ROC) curves for the risk scores with and without coronary artery calcium (CAC) applied within the
MESA (Multi-Ethnic Study of Atherosclerosis) cohort. (Right) A boxplot of the predicted 10-year coronary heart disease (CHD) probabilities for
each score stratiﬁed by event status. The shaded box covers the middle 50% of the data. AUC ¼ area under the curve.
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1648excellent discrimination and calibration for the model
including CAC. Harrell’s C-statistic was 0.779 in the
HNR study and 0.816 in the DHS. There was a 7.8% to
9.5% difference in predicted probability between
events and nonevents. Observed and predicted risks
were close across the range of the score, as seen in the
Central Illustration, with the exception of some un-
derestimation seen in the highest risk group of DHS.
There was no evidence of poor calibration based
on the Hosmer-Lemeshow goodness-of-ﬁt statistics
(p > 0.22 for each cohort). Externally validated cali-
bration slopes were 0.90 for HNR and 1.19 for DHS
(perfect calibration yields a slope of 1.0). Mean cali-
bration, or calibration-in-the-large, was excellent for
both studies (0.50% for HNR and 0.46% for DHS),TABLE 3 Evaluation of Model Performance
MESA HNR DHS
Sample size 6,726 3,692 1,080
CHD events, n 422 274 58
Model with risk factors only
Harrell’s C-statistic 0.750 0.720 0.782
Discrimination slope 0.052 0.053 0.046
Calibration slope 0.834 0.740 1.55
Model with risk factors and CAC
Harrell’s C-statistic 0.800 0.779 0.816
Discrimination slope 0.086 0.095 0.078
Calibration slope 0.857 0.899 1.19
Abbreviations as in Tables 1 and 2.indicating that on average, predicted risk was within
one-half of a percent of the observed event rate. In
comparison, the model without CAC also was not as
well calibrated in HNR (calibration slope 0.74), and
discrimination was substantially worse (C-statistic ¼
0.720, discrimination slope 0.053). In DHS, the
C-statistic for the model without CAC was very good
(C-statistic ¼ 0.782) but the discrimination slope was
only 0.046, and the calibration slope was large at 1.55.
Figure 2 displays a sample patient case. A 70-year-
old Hispanic man with mild treated hypertension and
no other traditional risk factors would have a 10-year
CHD risk of 9.3% before considering CAC data and
3.1% after a CAC score result of 0.
DISCUSSION
CAC is a direct measurement of 1 component of
atherosclerotic plaque in the coronary arteries, and a
potent predictor of future CHD events (1–11). Risk
prediction equations are recommended for clinical
use to select the best candidates for preventive
therapies such as cholesterol-lowering medications
(30). One commonly stated limitation for clinical CAC
scoring is the absence of a risk calculator for inte-
grating this information into global cardiovascular
risk assessment (31). Here, we present a predictive
algorithm to integrate CAC measurement with tradi-
tional risk factors and demonstrate that a risk score
that includes CAC improves CHD risk prediction
compared with single measurements of traditional
CENTRAL ILLUSTRATION MESA CHD Risk Score Using CAC: Calibration of the MESA CHD Risk Score
McClelland, R.L. et al. J Am Coll Cardiol. 2015; 66(15):1643–53.
The observed versus the predicted event rates are presented. Predicted risks were divided into 10 equal sized bins for the MESA (Multi-Ethnic
Study of Atherosclerosis) and HNR (Heinz Nixdorf Recall Study). For the DHS (Dallas Heart Study), only 5 bins were used due to the smaller
sample size. CAC ¼ coronary artery calcium; CHD ¼ coronary heart disease.
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FIGURE 2 Online Risk Score Calculator
A screenshot of the online risk score calculator on the MESA Website. Here we see the calculator being used for an older man with fairly
favorable risk factor proﬁle but 0 CAC. Under a risk score without CAC, 10-year estimated CHD risk is 9.3%, due in large part to his age.
Once we factor in that he has no detectable CAC, estimated risk is only 3.1%. HDL ¼ high-density lipoprotein cholesterol; other abbreviations
as in Figure 1.
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considered as part of the “risk discussion” between a
clinician and patient when CAC imaging has been
performed (33).
We also show that the algorithm generalizes well to
2 external populations. These validation cohorts
included 1 large study in Germany (HNR) that follows
very similar protocols to MESA and has similar age
and risk factor distribution. The second validation
cohort, the DHS, is U.S.-derived and multiethnic,
similar to MESA and the U.S. population. Our algo-
rithm includes a term for race/ethnicity; however,
consistent with an earlier report from MESA by
Detrano et al. (1), we did not ﬁnd that the associations
of CAC or other risk factors with CHD events differed
by race/ethnicity. Our results are consistent with
prior studies demonstrating that CAC improves
discrimination of CHD events in the MESA population
and the HNR study (2,4–11).
We evaluated 2 important aspects of a risk pre-
diction algorithm: discrimination and calibration.Discrimination refers to the ability of the risk score to
separate those who ultimately have events from
those who do not. The statistics that reﬂect this
are the C-statistic and the discrimination slope. C-
statistics for existing risk scores, including the
Framingham CHD risk score and the 2013 American
College of Cardiology (ACC)/American Heart Associa-
tion (AHA) risk estimator, evaluated in the MESA data
fall in the range of 0.65 to 0.75 depending on the
subset being investigated (34). Improvement to the
0.78 to 0.81 range, as demonstrated in our 2 external
validations, represents a substantial gain in terms of
this metric. We also note that comparing discrimina-
tion with a recalibrated AHA/ACC risk score (30) (C-
index 0.71) to a strategy of adding CAC to the AHA/
ACC score (C-index 0.78) to our risk score (C-index
0.80) supports the strategy of deriving a new score to
incorporate CAC, rather than attempting to simply
add CAC onto the existing risk score.
The discrimination slope represents the separa-
tion between events and nonevents in terms of
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who experience events will have predicted 10-year
risk estimates that are on average 8% to 9% higher
than the nonevent group. Importantly, the MESA
CHD risk score with CAC offers a substantial
improvement in separation. Finally, calibration re-
fers to the agreement between observed and pre-
dicted event rates in the population. The HNR
validation results indicate excellent calibration, and
the DHS results indicate very good calibration. This
is important, as the AHA/ACC risk score is known to
overestimate risk and exhibit poor calibration in
MESA (34).
Traditional CHD risk scores are strongly inﬂuenced
by age, sex, and race/ethnicity. Importantly, in-
cluding CAC in the risk score markedly decreases the
effect of these demographic risk factors (Table 2). This
is likely explained by the fact that CAC serves to
integrate the effect of all measured (and unmeasured)
risk factors over the course of an individual’s lifetime
up until the point of CAC measurement. This is
important in terms of individualization of risk, and
avoids scenarios where, for instance, all men over a
particular age are deemed high risk based on their
chronological age alone.
We also considered a direct comparison with
existing risk scores; however, several factors limit our
enthusiasm for this comparison. Existing risk scores
have been shown to be poorly calibrated and/or have
low discrimination in MESA (34), and thus, compari-
son of any new score developed in MESA (even in the
absence of CAC) is guaranteed to show improvement.
It would be unclear if this improvement is the result
of an improved score, the addition of CAC, a problem
with the original score, or some combination of these
and other factors. In other words, comparing to an
existing score would likely overstate the added value
due to inclusion of CAC. For this reason, we opted to
make our comparison with a MESA version of a risk
score, developed using the same modeling strategy as
the CAC enhanced score—improvements in prediction
of CHD events over this score are clearly due to the
addition of CAC to the risk scoring paradigm. Our goal
here was not to develop a new score with traditional
risk factors only, but to provide an appropriate
baseline for evaluation of our new score that in-
corporates CAC.
We included family history because it is a strong
independent predictor of risk and is easily obtainable
with no additional testing. We opted to include CAC
as the sole marker of subclinical disease as it has been
shown to offer the largest incremental prediction
improvement over traditional risk factors. There may
be potential utility in exploring whether othersubclinical measures (i.e., ankle-brachial index, ca-
rotid plaque, ECG abnormalities) offer further incre-
mental improvement in future MESA risk scores
modeling stroke or a more inclusive CVD outcome.
Existing risk scores differ in their choice of
endpoint. We modeled a CHD endpoint, similar to the
Framingham risk score as described in the Adult
Treatment Panel III (ATP 3) report (35), but dissimilar
to other risk scores that also include stroke (30,36,37),
angina (38,39), and other events such as peripheral
vascular disease, transient ischemic attack, and heart
failure (39). We opted against using a composite CVD
endpoint, because each CVD component has different
associations with risk factors. In addition, CAC has
been shown to be much more strongly associated
with CHD events than with cerebrovascular disease
(40) and is more likely to be used clinically for CHD
risk prediction.
The algorithm is a prediction tool, and the terms in
the model should not be interpreted causally. For
example, the term for antihypertensive medications
denotes an increased risk for those on medications.
This reﬂects the fact that those with treated hyper-
tension tend to be a higher-risk population, not that
the medications themselves increase their risk. The
term captures a combination of the increased risk of
this population and the beneﬁcial effect the medica-
tion has for those taking it. Similar reasoning holds
for the effect of lipid-lowering therapy. An additional
cautionary note is that the risk estimates will have
considerable variability in subsets of participants that
are rare in the development data. For instance, par-
ticipants with very high CAC (>400 or >1,000) despite
having a “normal” risk factor proﬁle are rare in
MESA. For participants with more “typical” risk factor
proﬁles, the accuracy of the risk estimate will be
optimized.
The MESA study includes many participants that
were taking blood pressure or lipid-lowering medi-
cation at the baseline examination. A strength of the
MESA risk score is that it remains relevant for these
commonly encountered patients, many of whom are
treated for hypertension and/or hypercholesterole-
mia at the time of the initial encounter. For example,
the risk scores can be used by the physician to moti-
vate patient life-style change, encourage adherence
to existing therapy, or to guide decisions about
treatment intensity. The MESA risk score may be
valuable for guiding decisions about the net beneﬁt of
daily aspirin therapy in primary prevention (41).
When making treatment initiation decisions, the
value of lipid-lowering or antihypertensive medica-
tions can simply be entered as “zero.” This allows the
risk score to be useful in more situations.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Detection of CAC by
computed tomography imaging can add to traditional
risk factors for prediction of ischemic risk, but no
validated method other than the MESA risk score has
been available to incorporate the CAC score in esti-
mating an individual’s 10-year risk of coronary events.
TRANSLATIONAL OUTLOOK: Prospective studies
are needed to validate the MESA risk score in inde-
pendent cohorts, enhance the clinical application of
CAC scoring in cardiovascular risk assessment, and
inform the integration of this approach in future pre-
vention guidelines.
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1652STUDY STRENGTHS AND LIMITATIONS. Strengths of
this study include the large, modern, community-
based multiethnic cohort and the use of statistical
techniques to provide a model that performs well
when applied outside of the development cohort.
Independent validation of the model in 2 contempo-
rary cohorts—1 international from Germany and 1
U.S.-based multiethnic study—provides evidence of
external validity. The age range of MESA was 45 to 84
years at study baseline, and hence, the algorithm is
limited to this range. Although MESA is multiethnic,
there are many race/ethnicities not represented in the
study, and the utility of the algorithm in these groups
is unknown. Limitations of this study exist. The
development cohort consisted of individuals aged 45
to 85 and in 1 of 4 race/ethnic groups. The general-
izability of the score outside of these demographics is
unknown. Additionally, our external validation co-
horts did not include Chinese participants.
CONCLUSIONS
TheMESACHD risk score is theﬁrst available algorithm
incorporating CAC with traditional risk factors for 10-
year risk prediction. In addition to its use in direct
clinical encounters, theMESA risk score can be used by
radiologists and cardiologists when interpreting and
reporting CAC scores. Similar to the current practice of
reporting CACpercentiles or “arterial age” to place CAC
results into clinical context, scan readers can now
calculate and provide a “post-test” 10-year CHD risk
after CAC scanning based on the MESA risk score. This
updated 10-year risk could be used to help make ther-
apeutic decisions, such as the decision to start statin or
aspirin therapy in primary prevention. Future guide-
lines from the Society of Cardiovascular ComputedTomography might consider recommending this
practice in routine CAC score reporting. Additionally,
future iterations of U.S. and international prevention
guidelines may consider use of the MESA risk score as
an alternative risk score to existing algorithms when
CAC score results are available.
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